If CP-COV03 is approved as a treatment for monkeypox with the FDA's fast-track designation, we will witness the birth of another innovative antiviral drug comparable to penicillin: the epitome of the 20th century's wonder antibiotics.’ In December 2021, the company reported that CP-COV03 plus dexamethasone had been effective against severe COVID-19 patients, another clinical success for an IA/magic shield combinatory treatment regimen [252]. Here, CP is linked to COVID-19.